infoJustice

Documents from State Legislators

• Letter to President Obama from VT Governor Peter Shumlin on Pharmaceuticals and the Trans Pacific Partnership June 1st, 2011
• Letter from ME State Rep. Sharon Treat and the Forum on Democracy and Trade to Rep. Waxman May 3rd, 2011
• Submission by NLARx and the Forum on Democracy and Trade
• National Legislative Association on Prescription Drug Prices Resolution Opposing the Inclusion of a Pharmaceuticals Chapter in the Trans Pacific Partnership January 24th, 2011
• January 21, 2011. National Legislative Association for Prescription Drug Prices Resolution Opposing the Inclusion of a Pharmaceuticals Chapter in the Trans-Pacific Partnership.
• Letter from state Representatives Sharon Anglin Treat (ME), Ginny Lyons (VT), Kathleen C. Keenan (VT), Charles F. Weed (NH), and State Senator Peggy Rotundo (ME) to U.S. Trade Representative Ron Kirk. September 16, 2010.
• Letter from VT State Senator Ginny Lyons and VT State Representative Keenan to President Obama. August 27, 2010.
• Letter from VT Governor Douglas to DHHS Secretary Kathleen Sebelius. May 3, 2010.
• Letter from ME Governor Baldacci to DHHS Secretary Kathleen Sebelius. April 27, 2010.
• Testimony to Interagency Special 301 Panel. March 3, 2010:
  • Sean Flynn for Forum on Democracy and Trade
  • Maine State Rep. Sharon Treat for the Maine Citizens Trade Policy Commission
  • Maine State Rep. Sharon Treat for the NLARx Working Group on Trade
  • Robin Lunge for the Vermont Commission on International Trade and State Sovereignty
• Written Submissions to the U.S. Trade Representative for the 2010 Special 301 Report:
  • Joint submissions of the National Legislative Association on Prescription Drug Prices Working Group on Trade, the Vermont Commission on International Trade and State Sovereignty, and the Forum on Democracy and Trade.
  • Maine Citizen Trade Policy Commission
  • National Legislative Association on Prescription Drug Prices (NLARx)
  • Vermont Commission on International Trade and State Sovereignty
• National Legislative Association on Prescription Drug Prices.  Comments to USTR regarding the Korea-US Free Trade Agreement. September 15, 2009.
• ME State Rep. Sharon Treat and AZ State Sen. Meg Burton Cahill, Letter to Stanford Professor John Barton on his proposal for a trade agreement to limit reference pricing of drugs, (May 18, 2009).
• Transcript of Sharon Treat’s Remarks on the Panel Achieving Innovation + Access in Global Pharmaceutical Markets. Washington College of Law, (February 19, 2009).
• Letter from Ginny Lyons, VT State Senator, and Kathleen Keenan, VT State Representative, to Sens. Patrick Leahy and Bernard Sanders, and Rep. Peter Welsh. April 18, 2007.
• Testimony of Sean Flynn on Behalf of the National Legislative Association on Prescription Drug Prices and the Forum on Democracy and Trade before the U.S. House Committee on Ways and Means.  March 20, 2007.
• Letter from Meg Burton Cahill, AZ State Senator, and Kevin Ryan, CT State Representative, to Rep. Sander Levin and the House Ways and Means Subcommittee on Trade, (March 18, 2007).
• Letter from Sharon Treat and Sean Flynn to U.S. Senate Finance Committee on Prescription Drug Price Negotiation (January 11, 2007).
• Letter from WA Governonr Christine Gregoire to U.S. Trade Representative Rob Portman. March 13, 2006.
• Letter from WA State Representatives Paull Shin, Maralyn Chase, Dawn Morrell and Tami Green to their federal Congressional delegation.  March 2, 2006.
• Letter from California state Senators Figuera and Kuehl to U.S. Trade Representative Robert Zoellick. February 16, 2005.
• Letter from NLARx Legislative Working Group on Trade and Prescription Drugs to US Trade Representative Ron Portman.  Signed by stat Representatives Kevin Ryan (CT), Meg Burton-Cahill (AZ), Roy Takumi (HI), Maralyn Chase (WA), David Guttenberg (AK), and John Patrick (ME), and State Senators Mark Montigny (MA), Liz Figueroa (CA), and Dan Foster (WV). August 20, 2005.
• Vermont State Senate Joint Resolution Relating to International Trade Agreements and Pharmaceutical Drug Programs.  J.R.S. 50. 2005.

Civil Society Documents

• Civil Society Comments on the Trans-Pacific Partnership Agreement. May 20, 2011.
• Sign On Letter to Trade Ministers from 39 Civil Society Groups.  February 15, 2011.
• Forum on Democracy and Trade. “Trans-Pacific Partnership & U.S. State Efforts to Control Drug Prices.” August 2010.
• Forum on Democracy and Trade Handout on the TPP. April 2010.
• US Civil Society Platform on Trade Related Intellectual Property and Access to Medicines Issues. May 19, 2009.
• Transcript of Peter Riggs’ Remarks on the Panel Achieving Innovation + Access in Global Pharmaceutical Markets. Washington College of Law, February 19, 2009.
• NLARx Handout. “Brief Overview of Industry/Government Efforts to Undermine Evidence-Based Pricing and Reimbursement Policies.” February 19, 2009.

Federal Government Documents

• May 2, 2011. Special 301 Report.  (See pages 13-14).
• March 30, 2011. Excerpts from the 2011 National Trade Estimate Report on Foreign Trade Barriers.

Industry Documents

• PhRMA Comments to USTR for the 2011 Special 301 Report. February 2011.
• PhRMA Comments to USTR on the TPP. January 25, 2010.
• IP Task Force of the U.S. Business Coalition for TPP. Leaked memo to negotiators. “TPP Intellectual Property Negotiations.”December 2010.

PIJIP Documents

• Shape of U.S. TPP Pharmaceuticals Chapter Emerges. Sean Flynn. June 15, 2011.
• State and Consumer Opposition to Trade Agreement Restrictions on Pharmaceutical Reimbursement and Pricing Programs. March 2011.
• Trans-Pacific Partnership & U.S. State Efforts to Control Drug Prices
• Notes on the 2011 Special 301 Hearing
• PIJIP Press Release. “PIJIP Represents Public Health and States in Submissions to the United States Trade Representative.” February 19, 2010.